Inhaled corticosteroid and long-acting β2-agonist pharmacological profiles: effective asthma therapy in practice (Q38070204)

28 August 2017

1 reference

title

Inhaled corticosteroid and long-acting β2-agonist pharmacological profiles: effective asthma therapy in practice (English)

1 reference

fluticasone furoate/vilanterol

28 August 2017

1 reference

1 reference

ChEBI release 2020-05-28

1 reference

4

Leonardo Fabbri

1 reference

28 August 2017

Michael Tamm

1

1 reference

PubMed ID

23273165

28 August 2017

David H Richards

series ordinal

2

1 reference

PubMed ID

23273165

28 August 2017

Bianca Beghé

series ordinal

3

1 reference

28 August 2017

1 December 2012

1 reference

28 August 2017

1 reference

28 August 2017

106 Suppl 1

1 reference

28 August 2017

S9-19

1 reference

Combination inhalers containing inhaled corticosteroids and long-acting beta2-agonists: improved clinical efficacy and dosing options in patients with asthma

28 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Heterogeneity of response to asthma controller therapy: clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Safety of formoterol in patients with asthma: combined analysis of data from double-blind, randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Leukotriene antagonists as first-line or add-on asthma-controller therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Asthma Treatment Guidelines Meet the Real World

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

The salmeterol/fluticasone combination is more effective than fluticasone plus oral montelukast in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Tiotropium bromide step-up therapy for adults with uncontrolled asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Tiotropium in asthma poorly controlled with standard combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Lung function and asthma control with beclomethasone and formoterol in a single inhaler

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Persistence, adherence, and effectiveness of combination therapy among adult patients with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Treatment of moderate to severe asthma: patient perspectives on combination inhaler therapy and implications for adherence

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Adherence to asthma controller medication regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Beclomethasone/formoterol vs fluticasone/salmeterol inhaled combination in moderate to severe asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Beclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Risk-benefit value of inhaled glucocorticoids: a pharmacokinetic/pharmacodynamic perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Beyond the dogma: novel beta2-adrenoceptor signalling in the airways

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Interactions of glucocorticoids and beta 2-agonists

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Glucocorticoids induce beta2-adrenergic receptor function in human nasal mucosa

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Protective effects of a glucocorticoid on downregulation of pulmonary beta 2-adrenergic receptors in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Dexamethasone potentiates high-affinity beta-agonist binding and g(s)alpha protein expression in airway smooth muscle

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

The effect of corticosteroids on the disposal of long-acting beta2-agonists by airway smooth muscle cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Interaction between glucocorticoids and beta2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Long-acting beta2-adrenoceptor agonists synergistically enhance glucocorticoid-dependent transcription in human airway epithelial and smooth muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Anti-inflammatory activity of beta2-agonists in primary lung epithelial cells is independent of glucocorticoid receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Antiinflammatory effects of long-acting beta2-agonists in patients with asthma: a systematic review and metaanalysis

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

RETRACTED: Inhaled corticosteroids and long-acting beta-agonists in adult asthma: a winning combination in all?

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Airway smooth muscle dynamics: a common pathway of airway obstruction in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Impaired translation of CCAAT/enhancer binding protein alpha mRNA in bronchial smooth muscle cells of asthmatic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Dysfunctional interaction of C/EBPalpha and the glucocorticoid receptor in asthmatic bronchial smooth-muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

A Holy Grail of asthma management: toward understanding how long-acting beta(2)-adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Airway remodeling-associated mediators in moderate to severe asthma: effect of steroids on TGF-beta, IL-11, IL-17, and type I and type III collagen expression

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Co-deposition of salmeterol and fluticasone propionate by a combination inhaler

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Histone acetylation and deacetylation: importance in inflammatory lung diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Review of the molecular and cellular mechanisms of action of glucocorticoids for use in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Comparison of inhaled corticosteroids: an update

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Pharmacokinetic and pharmacodynamic properties of inhaled ciclesonide

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Bioavailability and metabolism of mometasone furoate: pharmacology versus methodology

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Comparative pharmacology, bioavailability, pharmacokinetics, and pharmacodynamics of inhaled glucocorticosteroids.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Development of fluticasone propionate and comparison with other inhaled corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Dynamic measurements of total hepatic blood flow with Phase Contrast MRI.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Structure-activity relationships of topically active steroids: the selection of fluticasone propionate

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Expression of the beta 2 adrenoceptor partial agonist/antagonist activity of salbutamol in states of low and high adrenergic tone

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Comparison of the Relative Efficacy of Formoterol and Salmeterol in Asthmatic Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Comparison of formoterol, salbutamol and salmeterol in methacholine-induced severe bronchoconstriction

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

A comparison of the onset of action of salbutamol and formoterol in reversing methacholine-induced bronchoconstriction

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Speeds of action of single doses of formoterol and salbutamol compared with placebo in reversing methacholine-induced bronchoconstriction

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Molecular mechanisms of beta(2)-adrenergic receptor function, response, and regulation

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Long duration of airway but not systemic effects of inhaled formoterol in asthmatic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Inhaled steroid/long-acting beta 2 agonist combination products provide 24 hours improvement in lung function in adult asthmatic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

The 24 h duration of bronchodilator action of the budesonide/formoterol combination inhaler

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Pharmacology and therapeutics of bronchodilators

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

β(2) -adrenoceptor agonists: current and future direction

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Pharmacological characterization of indacaterol, a novel once daily inhaled 2 adrenoceptor agonist, on small airways in human and rat precision-cut lung slices.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Lipid membrane interactions of indacaterol and salmeterol: do they influence their pharmacological properties?

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Inhaled corticosteroids or long-acting beta-agonists alone or in fixed-dose combinations in asthma treatment: a systematic review of fluticasone/budesonide and formoterol/salmeterol

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

The safety of long-acting beta-agonists among patients with asthma using inhaled corticosteroids: systematic review and metaanalysis

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Fluticasone/formoterol: a new single-aerosol combination therapy for patients with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

The influence of lung deposition on clinical response.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Effects of bronchodilator particle size in asthmatic patients using monodisperse aerosols

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

In vitro/in vivo comparisons in pulmonary drug delivery

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Therapeutic significance of distal airway inflammation in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Update on the roles of distal airways in asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Do all dry powder inhalers show the same pharmaceutical performance?

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Not all asthma inhalers are the same: factors to consider when prescribing an inhaler

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

The Diskus: a review of its position among dry powder inhaler devices

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Modulite: a simple solution to a difficult problem

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

Duration of effect of single-dose inhaled fluticasone propionate on AMP-induced bronchoconstriction.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2812%2970005-7

7 January 2021

10.1016/S0954-6111(12)70005-7

Identifiers

DOI

1 reference

28 August 2017

1 reference

PubMed ID

23273165